77 Antiplatelet and Anticoagulant Bleeding Risk Reduction: A Collaborative Approach

Introduction: Dual antiplatelet/anticoagulant (APT/AC) therapy increases the risk of bleeding significantly. Evidence-based literature regarding the indication and length of therapy for APT has changed in recent years. Medical complexity of patients, self-referred care, and Care in the Community have made it more challenging for providers to consistently evaluate APT indications and overall risk/benefit of therapy. The objective was to create standardized workflow to assist Patient Aligned Care Team (PACT) in the review of appropriateness of long-term APT therapy.